Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery
Launched by DR ABDURRAHMAN YURTASLAN ANKARA ONCOLOGY TRAINING AND RESEARCH HOSPITAL · May 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a condition called sarcopenia, which is the loss of muscle mass and strength, affects the use of muscle relaxants during surgery for gastrointestinal cancer. The researchers want to see if patients with sarcopenia respond differently to these medications compared to those without it. To do this, they will take a special scan of the abdomen before surgery to determine who has sarcopenia. The trial will help improve anesthesia care for patients by ensuring that their individual needs are met during surgery.
To be eligible for this study, participants must be between 18 and 75 years old, have a diagnosis of gastrointestinal cancer, and be scheduled for elective surgery. They should also have had a specific imaging test called a CT scan before their surgery. However, individuals with certain conditions, such as neuromuscular diseases or severe organ failure, will not be able to take part in the trial. If you join the study, you can expect to have your muscle response to anesthesia carefully monitored during your surgery, which may help improve safety and outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged between 18 and 75 years Patients diagnosed with gastrointestinal system (GIS) cancer and scheduled for elective surgery Patients who have undergone preoperative abdominal computed tomography (CT) imaging Patients classified as American Society of Anesthesiologists (ASA) physical status I-III
- Exclusion Criteria:
- • Patients with a history of neuromuscular diseases Patients receiving chronic steroid or immunosuppressive therapy Patients with electrolyte imbalance Patients using medications that affect neuromuscular transmission Patients with severe organ failure in the preoperative period (e.g., liver or renal failure) Patients who refuse to participate in the study Patients requiring emergency surgery Patients using muscle relaxants in the preoperative period
About Dr Abdurrahman Yurtaslan Ankara Oncology Training And Research Hospital
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital is a leading institution dedicated to advancing cancer care and research in Turkey. With a strong focus on innovative oncology treatments and comprehensive training programs, the hospital serves as a pivotal center for clinical trials aimed at improving patient outcomes. Its multidisciplinary team of specialists collaborates to explore cutting-edge therapeutic approaches, ensuring adherence to the highest standards of clinical research and patient safety. The hospital's commitment to excellence positions it as a key player in the global oncology research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Yenimahalle, Turkey
Patients applied
Trial Officials
Mustafa Kemal SAHIN
Principal Investigator
Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation
Mensure KAYA
Principal Investigator
Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation
Belkis YILMAZ
Principal Investigator
Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation
Ahmet BAYRAK
Principal Investigator
Ankara Oncology Education and Research Hospital Clinic of Radiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported